TriSalus Life Sciences Presents Liver and Pancreatic Cancer Data at ASCO 2024

6/3/24 7:08:24 AM ET

Medical Specialities

Health Care

Get the next $TLSI alert in real time by email

TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that data from its Phase 1b PERIO-02 clinical trial was presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois.

The PEDD approach is a proprietary delivery mechanism developed by TriSalus that aims to overcome challenges of the tumor microenvironment (TME) by modulating pressure and flow to enhance local drug concentrations in tumors by improving intravascular therapeutic delivery. The PERIO-02 clinical trial is the hepatic arterial infusion (HAI) of nelitolimod with the PEDD method to enhance tumor response in combination with intravenous checkpoint inhibition in adults with Hepatocellular Carcinoma (HCC) or Intrahepatic Cholangiocarcinoma (ICC).

Get the next $TLSI alert in real time by email

Date	Price Target	Rating	Analyst
11/11/2024	$11.00	Buy	ROTH MKM
10/25/2024	$12.50	Outperform	Northland Capital
9/16/2024	$10.00	Outperform	Oppenheimer
5/30/2024	$12.00	Buy	Canaccord Genuity

TriSalus Life Sciences Presents Liver and Pancreatic Cancer Data at ASCO 2024

Chat with this insight

Recent Analyst Ratings for $TLSI

$TLSI Market Insights

Live Market Insights

Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Maintains $12 Price Target

TriSalus Life Sciences Presents Liver and Pancreatic Cancer Data at ASCO 2024

Canaccord Genuity Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $12

$TLSI Press Releases

Fastest customizable press release news feed in the world

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

$TLSI Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by TriSalus Life Sciences Inc.

$TLSI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

Northland Capital initiated coverage on TriSalus Life Sciences with a new price target

Oppenheimer initiated coverage on TriSalus Life Sciences with a new price target

$TLSI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$TLSI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$TLSI SEC Filings

$TLSI Financials

Live finance-specific insights

CEO AND PRESIDENT Szela Mary T bought $75,359 worth of shares (14,815 units at $5.09), increasing direct ownership by 4% to 384,677 units (SEC Form 4)

CEO AND PRESIDENT Szela Mary T bought $24,850 worth of shares (5,000 units at $4.97), increasing direct ownership by 1% to 369,862 units (SEC Form 4)

SR.VP, CORP. DEV. & STRATEGY Marshak Richard was granted 6,875 shares, increasing direct ownership by 25% to 34,126 units (SEC Form 4)

CEO AND PRESIDENT Szela Mary T bought $75,359 worth of shares (14,815 units at $5.09), increasing direct ownership by 4% to 384,677 units (SEC Form 4)

CEO AND PRESIDENT Szela Mary T bought $24,850 worth of shares (5,000 units at $4.97), increasing direct ownership by 1% to 369,862 units (SEC Form 4)

SEC Form 10-Q filed by TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form EFFECT filed by TriSalus Life Sciences Inc.

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

TriSalus Reports Q2 2024 Financial Results and Business Update

$TLSI Leadership Updates

Live Leadership Updates

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics

Recent Analyst Ratings for
$TLSI

$TLSI
Market Insights

$TLSI
Press Releases

$TLSI
Large Ownership Changes

$TLSI
Analyst Ratings

$TLSI
Insider Purchases

$TLSI
Insider Trading

$TLSI
SEC Filings

$TLSI
Financials

$TLSI
Leadership Updates